RxDoctor Payments Data

Glen Henry

Interventional Cardiology · Gainesville, GANPI 1720077324

Payments from drug & device makers

$19,525in general payments, 2019–2025

Across 92 payments — averaging $212.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$12K
  • Bard Peripheral Vascular, Inc.$3K
  • Abiomed$934
  • Shockwave Medical, Inc$743
  • Asahi Intecc USA, Inc.$627
  • Philips North America LLC$389
  • plus $2K from 13 others

What the payments were for

  • Travel & lodging$3898%
  • Food & beverage$4,78692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,525 in reported general payments places this provider in the 65th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$118,000
Medicare patients
1,159
Services billed
1,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol31$33,021
JardianceEmpagliflozin12$12,450
EliquisApixaban12$12,087
BrilintaTicagrelor18$10,254
Repatha SureclickEvolocumab16$8,667
NexletolBempedoic Acid12$4,604
Ezetimibe78$1,366
ClopidogrelClopidogrel Bisulfate144$1,350
Metoprolol Succinate77$791
Rosuvastatin Calcium73$743
Atorvastatin Calcium38$381
Losartan Potassium40$331
Spironolactone46$331
Carvedilol62$312
Lisinopril30$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$41$43,27549 claims
PfizerEliquis$63$12,08712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →